drugset / Trial / NCT04130594
Study of Safety and Immunogenicity of BVRS-GamVac
Phase 1/2
Unknown
162 enrolled
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
RandomizedParallel-groupSingle-blindPrevention
Summary
The Middle East respiratory syndrome coronavirus (MERS-CoV) was identified in 2012 during the first Middle East respiratory syndrome (MERS) outbreak. MERS-CoV causes an acute lower-respiratory infection in humans, with a fatality rate of \~34.5%. The aim of the study is to assess the safety and immunogenicity of adenoviral-based vaccine against MERS - BVRS-GamVac.
Timeline
- Start
- 2019-11-07
- Primary completion
- 2021-07-01
- Completion
- 2021-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BVRS-GamVac | Vaccine | — | Intramuscular |